Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. Aug 15, 2025; 17(8): 108484
Published online Aug 15, 2025. doi: 10.4251/wjgo.v17.i8.108484
Published online Aug 15, 2025. doi: 10.4251/wjgo.v17.i8.108484
Table 1 Baseline characteristics, n (%)
| Characteristic | Total | Characteristic | Total |
| Gender | Classification | ||
| Male | 38 (86.36) | Nonsquamous | 4 (9.09) |
| Female | 6 (13.64) | Squamous | 40 (90.91) |
| Median age, year | 64.0 (59.09-68.0) | Immunotherapy | |
| Age, year | Sindilizumab | 11 (25.0) | |
| ≤ 60 | 12 (27.27) | Karelizumab | 1 (2.27) |
| > 60 | 32 (72.73) | Tirelizumab | 18 (40.91) |
| T stage | Pabolizumab | 1 (2.27) | |
| 1b | 6 (13.64) | Teraplizumab | 10 (22.73) |
| 2 | 7 (15.91) | Others | 3 (6.82) |
| 3 | 31 (70.45) | Joint plan | |
| N stage | No | 3 (6.82) | |
| 0 | 11 (25.0) | CT | 29 (65.91) |
| 1 | 16 (36.36) | RT | 2 (4.55) |
| 2 | 9 (20.45) | RCT | 10 (22.73) |
| 3 | 8 (18.18) | Recurrence | |
| Differentiation | No | 35 (79.55) | |
| High | 9 (20.45) | Original | 2 (4.55) |
| Median | 21 (47.73) | Distant | 7 (15.91) |
| Low | 14 (31.82) |
- Citation: Li LY, Zhang MQ, Ying WM, Zhang WZ, Jiang WJ, Xiong TJ, Wang FM, Fu ZC. Postoperative adjuvant PD-1 immunotherapy survival and body-mass-index dynamics in esophageal cancer: A real-world retrospective study. World J Gastrointest Oncol 2025; 17(8): 108484
- URL: https://www.wjgnet.com/1948-5204/full/v17/i8/108484.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i8.108484